Liminatus Pharma (LIMN) Liabilities and Shareholders Equity (2024 - 2026)

Liminatus Pharma has reported Liabilities and Shareholders Equity for 3 years, with the latest figure at $2.8 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity changed N/A year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 million (up 21.18% YoY) and the FY2025 annual result came in at $512795.0, down 90.52% from the prior year.
• Liabilities and Shareholders Equity rose to $2.8 million in Q1 2026 per LIMN's latest filing, from $512795.0 in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $5.4 million in Q4 2024 and troughed at $512795.0 in Q4 2025.
• A 3-year average of $2.4 million and a median of $1.9 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The widest YoY moves for Liabilities and Shareholders Equity: up 90.52% in 2025, down 90.52% in 2025.
• Over 3 years, Liabilities and Shareholders Equity stood at $5.4 million in 2024, then slumped by 90.52% to $512795.0 in 2025, then jumped by 444.13% to $2.8 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $2.8 million, $512795.0, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.